iTeos Therapeutics is a common spin-off of het Ludwig Institute for Cancer Research (L.I.C.R.) and the Duve Institute of the Université Catholique de Louvain (U.C.L.). The goal is to combine their expertise in immunotherapy and tumor immunology for the development of innovative anti-cancer treatments.
